The diagnosis and management of acute and chronic urticaria

2014 update

Jonathan A. Bernstein, David M. Lang, David A. Khan, Timothy Craig, David Dreyfus, Fred Hsieh, Javed Sheikh, David Weldon, Bruce Zuraw, David I. Bernstein, Joann Blessing-Moore, Linda Cox, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Christopher R. Randolph, Diane E. Schuller, Sheldon L. Spector, Stephen A. Tilles, Dana Wallace

Research output: Contribution to journalArticle

261 Citations (Scopus)

Abstract

These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and ACAAI have jointly accepted responsibility for establishing "The diagnosis and management of acute and chronic urticaria: 2014 update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. The JTFPP understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or agent's cost is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In extraordinary circumstances, when the cost/benefit ratio of an intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The JTFPP is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the workgroup convened to draft the parameter, the task force reviewers, and peer review by members of each sponsoring society. Although the task force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments, when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameter workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Work Group chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias. Practice parameters are available online at www.jcaai.org and www.allergyparameters.org.

Original languageEnglish (US)
Pages (from-to)1270-1277.e66
JournalJournal of Allergy and Clinical Immunology
Volume133
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Urticaria
Advisory Committees
Joints
Allergy and Immunology
Conflict of Interest
Hypersensitivity
Asthma
Pharmaceutical Economics
Costs and Cost Analysis
Health Insurance Reimbursement
Peer Review
Disclosure
Routine Diagnostic Tests
Pharmaceutical Preparations
Cost-Benefit Analysis
Publications
Organizations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., ... Wallace, D. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology, 133(5), 1270-1277.e66. https://doi.org/10.1016/j.jaci.2014.02.036
Bernstein, Jonathan A. ; Lang, David M. ; Khan, David A. ; Craig, Timothy ; Dreyfus, David ; Hsieh, Fred ; Sheikh, Javed ; Weldon, David ; Zuraw, Bruce ; Bernstein, David I. ; Blessing-Moore, Joann ; Cox, Linda ; Nicklas, Richard A. ; Oppenheimer, John ; Portnoy, Jay M. ; Randolph, Christopher R. ; Schuller, Diane E. ; Spector, Sheldon L. ; Tilles, Stephen A. ; Wallace, Dana. / The diagnosis and management of acute and chronic urticaria : 2014 update. In: Journal of Allergy and Clinical Immunology. 2014 ; Vol. 133, No. 5. pp. 1270-1277.e66.
@article{4f19f7ff83a84c93aefb4075ee242624,
title = "The diagnosis and management of acute and chronic urticaria: 2014 update",
abstract = "These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and ACAAI have jointly accepted responsibility for establishing {"}The diagnosis and management of acute and chronic urticaria: 2014 update.{"} This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. The JTFPP understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or agent's cost is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In extraordinary circumstances, when the cost/benefit ratio of an intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The JTFPP is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the workgroup convened to draft the parameter, the task force reviewers, and peer review by members of each sponsoring society. Although the task force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments, when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameter workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Work Group chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias. Practice parameters are available online at www.jcaai.org and www.allergyparameters.org.",
author = "Bernstein, {Jonathan A.} and Lang, {David M.} and Khan, {David A.} and Timothy Craig and David Dreyfus and Fred Hsieh and Javed Sheikh and David Weldon and Bruce Zuraw and Bernstein, {David I.} and Joann Blessing-Moore and Linda Cox and Nicklas, {Richard A.} and John Oppenheimer and Portnoy, {Jay M.} and Randolph, {Christopher R.} and Schuller, {Diane E.} and Spector, {Sheldon L.} and Tilles, {Stephen A.} and Dana Wallace",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2014.02.036",
language = "English (US)",
volume = "133",
pages = "1270--1277.e66",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

Bernstein, JA, Lang, DM, Khan, DA, Craig, T, Dreyfus, D, Hsieh, F, Sheikh, J, Weldon, D, Zuraw, B, Bernstein, DI, Blessing-Moore, J, Cox, L, Nicklas, RA, Oppenheimer, J, Portnoy, JM, Randolph, CR, Schuller, DE, Spector, SL, Tilles, SA & Wallace, D 2014, 'The diagnosis and management of acute and chronic urticaria: 2014 update', Journal of Allergy and Clinical Immunology, vol. 133, no. 5, pp. 1270-1277.e66. https://doi.org/10.1016/j.jaci.2014.02.036

The diagnosis and management of acute and chronic urticaria : 2014 update. / Bernstein, Jonathan A.; Lang, David M.; Khan, David A.; Craig, Timothy; Dreyfus, David; Hsieh, Fred; Sheikh, Javed; Weldon, David; Zuraw, Bruce; Bernstein, David I.; Blessing-Moore, Joann; Cox, Linda; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher R.; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen A.; Wallace, Dana.

In: Journal of Allergy and Clinical Immunology, Vol. 133, No. 5, 01.01.2014, p. 1270-1277.e66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The diagnosis and management of acute and chronic urticaria

T2 - 2014 update

AU - Bernstein, Jonathan A.

AU - Lang, David M.

AU - Khan, David A.

AU - Craig, Timothy

AU - Dreyfus, David

AU - Hsieh, Fred

AU - Sheikh, Javed

AU - Weldon, David

AU - Zuraw, Bruce

AU - Bernstein, David I.

AU - Blessing-Moore, Joann

AU - Cox, Linda

AU - Nicklas, Richard A.

AU - Oppenheimer, John

AU - Portnoy, Jay M.

AU - Randolph, Christopher R.

AU - Schuller, Diane E.

AU - Spector, Sheldon L.

AU - Tilles, Stephen A.

AU - Wallace, Dana

PY - 2014/1/1

Y1 - 2014/1/1

N2 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and ACAAI have jointly accepted responsibility for establishing "The diagnosis and management of acute and chronic urticaria: 2014 update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. The JTFPP understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or agent's cost is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In extraordinary circumstances, when the cost/benefit ratio of an intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The JTFPP is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the workgroup convened to draft the parameter, the task force reviewers, and peer review by members of each sponsoring society. Although the task force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments, when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameter workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Work Group chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias. Practice parameters are available online at www.jcaai.org and www.allergyparameters.org.

AB - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and ACAAI have jointly accepted responsibility for establishing "The diagnosis and management of acute and chronic urticaria: 2014 update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. The JTFPP understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or agent's cost is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In extraordinary circumstances, when the cost/benefit ratio of an intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The JTFPP is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the workgroup convened to draft the parameter, the task force reviewers, and peer review by members of each sponsoring society. Although the task force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments, when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameter workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Work Group chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias. Practice parameters are available online at www.jcaai.org and www.allergyparameters.org.

UR - http://www.scopus.com/inward/record.url?scp=84899496074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899496074&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2014.02.036

DO - 10.1016/j.jaci.2014.02.036

M3 - Article

VL - 133

SP - 1270-1277.e66

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -